| Identification | Back Directory | [Name]
PDE9-IN-1 | [CAS]
2305087-92-5 | [Synonyms]
PDE9-IN-1
PDE-9-IN-1,PDE9IN1,PDE9 IN 1
4H-Pyrazolo[3,4-d]pyrimidin-4-one, 1-cyclopentyl-6-[[(1R)-2-[(3S)-3-fluoro-1-pyrrolidinyl]-1-methyl-2-oxoethyl]amino]-1,5-dihydro- | [Molecular Formula]
C17H23FN6O2 | [MDL Number]
MFCD32062828 | [MOL File]
2305087-92-5.mol | [Molecular Weight]
362.4 |
| Chemical Properties | Back Directory | [Boiling point ]
596.2±60.0 °C(Predicted) | [density ]
1.58±0.1 g/cm3(Predicted) | [form ]
Solid | [pka]
1.00±0.20(Predicted) | [color ]
White to off-white |
| Hazard Information | Back Directory | [Uses]
PDE9-IN-1 is a potent, selective, and orally bioavailable phosphodiesterase-9A (PDE9A) Inhibitor with an IC50 of 8.7 nM[1]. | [in vivo]
PDE9-IN-1 (2.5 and 5.0 mg/kg; Oral administration; daily for 21 days) effectively recovers learning and memory function[1]. | Animal Model: | Unilateral common carotid artery occlusion (UCCAO) mouse model[1] | | Dosage: | 2.5 and 5.0 mg/kg | | Administration: | Oral administration; daily for 21 days | | Result: | Significantly reduced the day 6 escape latency time and increased the frequency of platform area crossings, and recovered learning and memory function. High dose group possibly improved the escape latency time of mice. |
| [IC 50]
PDE9A: 8.7 nM (IC50) | [References]
[1] Wu Y, et al. Discovery of Potent, Selective, and Orally Bioavailable Inhibitors against Phosphodiesterase-9, a Novel Target for the Treatment of Vascular Dementia. J Med Chem. 2019 Apr 25;62(8):4218-4224. DOI:10.1021/acs.jmedchem.8b01041 |
|
|